Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody
AssigneesMillennium Pharmaceuticals, Inc., Theodor-Kocher Institute
InventorsMarcel Loetscher, Bernhard Moser, Shixin Qin, Charles R. Mackay
Life of this patent
Estimating the term…
Abstract
The present invention relates to proteins or polypeptides, referred to herein as isolated and/Or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.
Claims26
A method of inhibiting receptor function in an individual, comprising administering to said individual an effective amount of an antibody or antigen-binding fragment thereof which binds a human CXC Chemokine Receptor 3 (CXCR3) protein having the amino acid sequence of SEQ ID NO:2, wherein said antibody or antigen-binding fragment desensitizes CXCR3.
A method of inhibiting T cell activation in an individual, comprising administering to said individual an effective amount of an antibody or antigen-binding fragment thereof which binds human CXC Chemokine Receptor 3 (CXCR3) protein having the amino acid sequence of SEQ ID NO:2.
A method of inhibiting a function associated with T-cell activation, selected from the group consisting of cytokine production, cytotoxic T cell killing, and provision of T cell help, comprising administering to said individual an effective amount of an antibody or antigen-binding fragment thereof which binds CXC Chemokine Receptor 3 (CXCR3) protein having the amino acid sequence of SEQ ID NO:2.
A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof which binds human CXC Chemokine Receptor 3 (CXCR3) protein having the amino acid sequence of SEQ ID NO:2 and a parenteral or intravenous vehicle.
A method of antitumor therapy, comprising administering to a mammal a therapeutically effective amount of a promoter of a mammalian CXCR3 protein, other than a natural ligand of said protein.
A method of antiviral therapy, comprising administering to a mammal a therapeutically effective amount of a promoter of a mammalian CXCR3 protein, other than a natural ligand of said protein.
An antisense nucleic acid comprising a nucleic acid having a sequence that hybridizes to a nucleic acid having the sequence:
- a) SEQ ID NO:1,
- b) a portion thereof comprising the coding sequence,
- c) or an RNA counterpart of any one of (a) and (b).
A method for diagnosing a condition characterized by an increased level of activated T cells comprising providing a sample obtained from an individual;
- combining the sample and an antibody that binds human CXCR3 and quantifying cells that express CXCR3,
- wherein an increased level of cells that express CXCR3 relative to a suitable control is indicative of said condition.
Dependencies are inferred from the claim text.